The FDA approved a first-of-its-kind device, Medtronic’s MiniMed 670G hybrid closed looped system, that will automatically monitor glucose and provide basal insulin doses in patients aged ≥14 years with type 1 diabetes. The MiniMed 670G hybrid closed looped system acts as an artificial pancreas, with little or no input needed from the user.

On March 30, 2016, the FDA approved defibrotide sodium (Defitelio; Jazz Pharmaceuticals) for hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction after hematopoietic stem-cell transplant. This is the first drug approved for severe hepatic VOD. “The approval of Defitelio fills a significant need in the transplantation community to treat this rare but frequently fatal complication,” said Richard Pazdur, MD.

On January 21, 2015, secukinumab (Cosentyx; Novartis), a human IL-17A antagonist, was approved by the US Food and Drug Administration (FDA) for the treatment of adults with moderate-to-severe plaque psoriasis.

Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non–small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.